JP2020516617A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516617A5 JP2020516617A5 JP2019554986A JP2019554986A JP2020516617A5 JP 2020516617 A5 JP2020516617 A5 JP 2020516617A5 JP 2019554986 A JP2019554986 A JP 2019554986A JP 2019554986 A JP2019554986 A JP 2019554986A JP 2020516617 A5 JP2020516617 A5 JP 2020516617A5
- Authority
- JP
- Japan
- Prior art keywords
- pgdh inhibitor
- substituted
- pgdh
- aryl
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 heteroaryl aryl Chemical group 0.000 claims 18
- 108010051913 15-hydroxyprostaglandin dehydrogenase Proteins 0.000 claims 15
- 102100030489 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Human genes 0.000 claims 15
- 239000003112 inhibitor Substances 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 229910019142 PO4 Inorganic materials 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 235000021317 phosphate Nutrition 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 2
- 125000005277 alkyl imino group Chemical group 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000005133 alkynyloxy group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000001769 aryl amino group Chemical group 0.000 claims 2
- 125000005116 aryl carbamoyl group Chemical group 0.000 claims 2
- 125000004467 aryl imino group Chemical group 0.000 claims 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 2
- 125000005163 aryl sulfanyl group Chemical group 0.000 claims 2
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 231100000457 cardiotoxic Toxicity 0.000 claims 2
- 230000001451 cardiotoxic effect Effects 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 2
- RIFHJAODNHLCBH-UHFFFAOYSA-N methanethione Chemical group S=[CH] RIFHJAODNHLCBH-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- 102100028207 6-phosphogluconate dehydrogenase, decarboxylating Human genes 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 206010048610 Cardiotoxicity Diseases 0.000 claims 1
- 101710151348 D-3-phosphoglycerate dehydrogenase Proteins 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 claims 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 claims 1
- 229960004176 aclarubicin Drugs 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 229960002550 amrubicin Drugs 0.000 claims 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 235000013877 carbamide Nutrition 0.000 claims 1
- 210000004413 cardiac myocyte Anatomy 0.000 claims 1
- 231100000259 cardiotoxicity Toxicity 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000000394 phosphonato group Chemical group [O-]P([O-])(*)=O 0.000 claims 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims 1
- 229960001221 pirarubicin Drugs 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 150000003457 sulfones Chemical class 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 229960000653 valrubicin Drugs 0.000 claims 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
- 229960000641 zorubicin Drugs 0.000 claims 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022119729A JP2022141930A (ja) | 2017-04-07 | 2022-07-27 | 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483177P | 2017-04-07 | 2017-04-07 | |
| US62/483,177 | 2017-04-07 | ||
| PCT/US2018/026739 WO2018187810A1 (en) | 2017-04-07 | 2018-04-09 | Inhibitors of short-chain dehydrogenase activity for treating coronary disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022119729A Division JP2022141930A (ja) | 2017-04-07 | 2022-07-27 | 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516617A JP2020516617A (ja) | 2020-06-11 |
| JP2020516617A5 true JP2020516617A5 (cg-RX-API-DMAC7.html) | 2020-07-30 |
| JP7178360B2 JP7178360B2 (ja) | 2022-11-25 |
Family
ID=63712743
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554986A Active JP7178360B2 (ja) | 2017-04-07 | 2018-04-09 | 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤 |
| JP2022119729A Pending JP2022141930A (ja) | 2017-04-07 | 2022-07-27 | 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022119729A Pending JP2022141930A (ja) | 2017-04-07 | 2022-07-27 | 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11426420B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3606520A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7178360B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110891568A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018249956B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3059255A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018187810A1 (cg-RX-API-DMAC7.html) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
| US11718589B2 (en) | 2017-02-06 | 2023-08-08 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase |
| US12336982B2 (en) | 2018-11-21 | 2025-06-24 | Rodeo Therapeutics Corporation | Compositions and methods of modulating short-chain dehydrogenase activity |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014342811B2 (en) | 2013-10-15 | 2019-01-03 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
| CN118059093A (zh) | 2015-03-08 | 2024-05-24 | 卡斯西部储备大学 | 用于治疗纤维症的短链脱氢酶活性的抑制剂 |
| EP3606520A4 (en) | 2017-04-07 | 2021-01-06 | Case Western Reserve University | INHIBITORS OF SHORT CHAIN DEHYDROGENASE ACTIVITY FOR THE TREATMENT OF CORONARY DISEASES |
| AU2021211732A1 (en) | 2020-01-23 | 2022-08-25 | Myoforte Therapeutics, Inc. | PGDH inhibitors and methods of making and using |
| CA3183262A1 (en) | 2020-05-20 | 2021-11-25 | Rodeo Therapeutics Corporation | Compositions and methods of modulating short-chain dehydrogenase activity |
| WO2021252936A1 (en) * | 2020-06-11 | 2021-12-16 | The Board Of Trustees Of The Leland Stanford Junior University | Rejuvenation of aged tissues and organs by inhibition of the pge2 degrading enzyme, 15-pgdh |
| WO2022032230A1 (en) * | 2020-08-07 | 2022-02-10 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for treating neurodegeneration |
| WO2025170936A1 (en) * | 2024-02-05 | 2025-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | Materials and methods for treating cardiac dysfunction |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3532984A (en) | 1983-11-14 | 1985-05-23 | Dow Chemical Company, The | Method of preparing 1, 2, 4-triazolo (1, 5-a)- pyrimidine-2-sulfonyl chlorides |
| ATE119163T1 (de) | 1989-01-11 | 1995-03-15 | Ciba Geigy Ag | Antidots zur verbesserung der kulturpflanzenvertäglichkeit agrochemischer wirkstoffe. |
| EP0434624B1 (de) | 1989-12-22 | 1995-02-08 | Ciba-Geigy Ag | Triazolylsulfonamide |
| SE9303444D0 (sv) | 1993-10-20 | 1993-10-20 | Kabi Pharmacia Ab | New use of prostaglandins |
| US6080772A (en) | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| AU750039B2 (en) | 1997-02-04 | 2002-07-11 | Murray A. Johnstone | Method of enhancing hair growth |
| US20030096823A1 (en) | 2001-11-16 | 2003-05-22 | Beryl Asp | Method for the treatment of cardiotoxicity induced by antitumor compounds |
| ATE375349T1 (de) | 2002-08-02 | 2007-10-15 | Merck & Co Inc | Substituierte furo(2,3-b)pyridin derivate |
| WO2004089415A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST |
| JP2006522750A (ja) | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法 |
| EP1615697A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof |
| US7189724B2 (en) | 2003-04-15 | 2007-03-13 | Valeant Research And Development | Quinoxaline derivatives having antiviral activity |
| JP4783731B2 (ja) | 2003-08-29 | 2011-09-28 | ヴァーナリス（ケンブリッジ）リミテッド | ピリミドチオフェン化合物 |
| WO2006019832A1 (en) | 2004-07-22 | 2006-02-23 | Ptc Therapeutics, Inc. | Thienopyridines for treating hepatitis c |
| CA2593264C (en) | 2005-01-19 | 2012-09-25 | Merck & Co., Inc. | Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| WO2007072095A1 (en) | 2005-12-20 | 2007-06-28 | Richter Gedeon Nyrt. | New compounds |
| WO2009073460A2 (en) | 2007-12-03 | 2009-06-11 | Bausch & Lomb Incorporated | Inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 for ocular neuroprotection |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US9216983B2 (en) | 2007-12-21 | 2015-12-22 | Board Of Regents, University Of Texas System | Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity |
| WO2010077101A2 (ko) * | 2008-12-30 | 2010-07-08 | 조선대학교산학협력단 | 신규한 티아졸리딘디온 유도체 및 그의 용도 |
| HRP20150066T1 (hr) | 2009-09-29 | 2015-02-27 | Board Of Regents Of The University Of Texas System | Anti-malarijski agensi koji su inhibitori dihidroorotat dehidrogenaze |
| GB201107197D0 (en) | 2011-04-28 | 2011-06-15 | Cxr Biosciences Ltd | Compounds |
| ES2650230T3 (es) | 2011-09-23 | 2018-01-17 | Academisch Medisch Centrum | Materiales y métodos para pronóstico de evolución de esófago de Barrett |
| CA2861462A1 (en) | 2012-01-25 | 2013-08-01 | Proteostasis Therapeutics, Inc. | Proteasome activity modulating tricyclic compounds |
| HUE037262T2 (hu) * | 2012-04-16 | 2018-08-28 | Univ Case Western Reserve | Készítmények és 15-PGDH aktivitás modulálási módszerek |
| US9801863B2 (en) | 2012-04-16 | 2017-10-31 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis |
| AU2014342811B2 (en) | 2013-10-15 | 2019-01-03 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
| WO2015077382A2 (en) | 2013-11-19 | 2015-05-28 | Fight Against Cancer Innovation Trust | Combined cytology and molecular testing for early detection of esophageal adenocarcinoma |
| EP3131881A4 (en) | 2014-04-18 | 2017-09-06 | Millennium Pharmaceuticals, Inc. | Quinoxaline compounds and uses thereof |
| US10117842B2 (en) | 2014-08-12 | 2018-11-06 | The University Of Pécs (Pécsi Tudományegyetem) | Methods and materials for reducing ischemia-reperfusion injury |
| CN118059093A (zh) | 2015-03-08 | 2024-05-24 | 卡斯西部储备大学 | 用于治疗纤维症的短链脱氢酶活性的抑制剂 |
| AU2016248080A1 (en) | 2015-04-14 | 2017-11-02 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
| CN109072186B (zh) | 2016-03-04 | 2023-06-23 | 莱兰斯坦福初级大学评议会 | 利用前列腺素e2进行肌肉再生的组合物和方法 |
| JP7139308B2 (ja) | 2016-07-18 | 2022-09-20 | ケース ウエスタン リザーブ ユニバーシティ | 神経新生の促進及びニュ－ロン細胞死の阻害のための短鎖脱水素酵素活性の阻害剤 |
| JP7595413B2 (ja) | 2016-11-30 | 2024-12-06 | ケース ウエスタン リザーブ ユニバーシティ | １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用 |
| EP3576737A4 (en) | 2017-02-06 | 2021-04-21 | Case Western Reserve University | COMPOSITIONS AND METHODS OF MODULATING THE ACTIVITY OF SHORT CHAIN DEHYDROGENASE |
| EP3606520A4 (en) | 2017-04-07 | 2021-01-06 | Case Western Reserve University | INHIBITORS OF SHORT CHAIN DEHYDROGENASE ACTIVITY FOR THE TREATMENT OF CORONARY DISEASES |
| CN111132982A (zh) | 2017-05-26 | 2020-05-08 | 卡斯西部储备大学 | 调节短链脱氢酶活性的组合物和方法 |
| EP3883577A4 (en) * | 2018-11-21 | 2022-06-15 | Case Western Reserve University | COMPOSITIONS AND METHODS FOR MODULATION OF SHORT CHAIN DEHYDROGENASE ACTIVITY |
| JP2021134242A (ja) | 2020-02-25 | 2021-09-13 | 株式会社アイティー技研 | 鉱物油精製方法及び装置 |
| JP7574640B2 (ja) | 2020-12-23 | 2024-10-29 | 株式会社リコー | 画像処理装置、画像処理システム、方法およびプログラム |
-
2018
- 2018-04-09 EP EP18781322.5A patent/EP3606520A4/en active Pending
- 2018-04-09 JP JP2019554986A patent/JP7178360B2/ja active Active
- 2018-04-09 CN CN201880028200.4A patent/CN110891568A/zh active Pending
- 2018-04-09 AU AU2018249956A patent/AU2018249956B2/en active Active
- 2018-04-09 US US16/603,544 patent/US11426420B2/en active Active
- 2018-04-09 WO PCT/US2018/026739 patent/WO2018187810A1/en not_active Ceased
- 2018-04-09 CA CA3059255A patent/CA3059255A1/en active Pending
-
2022
- 2022-07-27 JP JP2022119729A patent/JP2022141930A/ja active Pending
- 2022-08-23 US US17/893,777 patent/US20230165883A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
| US11718589B2 (en) | 2017-02-06 | 2023-08-08 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase |
| US12336982B2 (en) | 2018-11-21 | 2025-06-24 | Rodeo Therapeutics Corporation | Compositions and methods of modulating short-chain dehydrogenase activity |